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Abstract  
Diphtheria anti-toxin (DAT) has been used to treat Corynebacterium diphtheriae infection for over 
one hundred years. While the global incidence of diphtheria has declined in the 20th century, the 
disease remains endemic in many parts of the world and significant outbreaks still occur.  
Diphtheria anti-toxin is an equine polyclonal antibody with considerable side effects that is in 
critically short supply globally. A safer, more readily available alternative to DAT would be 
desirable.   In the current study, we cloned human monoclonal antibodies (HuMabs) directly from 
antibody secreting cells of human volunteers immunized with Td vaccine. We isolated a diverse 
panel of HuMabs that recognized diphtheria toxoid and recombinant protein fragments of 
diphtheria toxin.  Forty-one unique HuMabs were expressed in 293T cells and tested for 
neutralization of diphtheria toxin in in vitro cytotoxicity assays. The lead candidate HuMab, 315C4 
potently neutralized diphtheria toxin with an EC50 of 0.65 ng/mL.  Additionally, 25 µg of 315C4 
completely protected guinea pigs in an in vivo lethality model.  In comparison, 1.6 IU of DAT was 
necessary for full protection resulting in an estimated relative potency of 64 IU/mg for 315C4. We 
further established that our lead candidate HuMab binds to the receptor binding domain of 
diphtheria toxin and blocks the toxin from binding to the putative receptor, heparin binding-
epidermal growth factor like growth factor.  The discovery of a specific and potent neutralizing 
antibody against diphtheria toxin holds promise as a potential human therapeutic and is being 
developed for human use.  
